The treatment of breast cancer in the era of precision medicine
The management of breast cancer, one of the most common and heterogeneous malignancies, has transformed with the advent of precision medicine. This review explores current developments in genetic profiling, molecular diagnostics, and targeted therapies that have revolutionized breast cancer treatmen...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2025-04-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/22/4/322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172878603943936 |
|---|---|
| author | Jingwen Bai Yiyang Gao Guojun Zhang |
| author_facet | Jingwen Bai Yiyang Gao Guojun Zhang |
| author_sort | Jingwen Bai |
| collection | DOAJ |
| description | The management of breast cancer, one of the most common and heterogeneous malignancies, has transformed with the advent of precision medicine. This review explores current developments in genetic profiling, molecular diagnostics, and targeted therapies that have revolutionized breast cancer treatment. Key innovations, such as cyclin-dependent kinases 4/6 (CDK4/6) inhibitors, antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs), have improved outcomes for hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes remarkably. Additionally, emerging treatments, such as PI3K inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and mRNA-based therapies, offer new avenues for targeting specific genetic mutations and improving treatment response, particularly in difficult-to-treat breast cancer subtypes. The integration of liquid biopsy technologies provides a non-invasive approach for real-time monitoring of tumor evolution and treatment response, thus enabling dynamic adjustments to therapy. Molecular imaging and artificial intelligence (AI) are increasingly crucial in enhancing diagnostic precision, personalizing treatment plans, and predicting therapeutic outcomes. As precision medicine continues to evolve, it has the potential to significantly improve survival rates, decrease recurrence, and enhance quality of life for patients with breast cancer. By combining cutting-edge diagnostics, personalized therapies, and emerging treatments, precision medicine can transform breast cancer care by offering more effective, individualized, and less invasive treatment options. |
| format | Article |
| id | doaj-art-60604dc5b9d24c7ba63cece9c86e0de5 |
| institution | OA Journals |
| issn | 2095-3941 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj-art-60604dc5b9d24c7ba63cece9c86e0de52025-08-20T02:19:58ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412025-04-0122432234710.20892/j.issn.2095-3941.2024.0510The treatment of breast cancer in the era of precision medicineJingwen Bai0Yiyang Gao1Guojun Zhang2The Breast Center of Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Peking University Cancer Hospital Yunnan, Kunming 650118, ChinaFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer, School of Medicine, Xiamen University, Xiamen 361100, ChinaThe Breast Center of Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Peking University Cancer Hospital Yunnan, Kunming 650118, ChinaThe management of breast cancer, one of the most common and heterogeneous malignancies, has transformed with the advent of precision medicine. This review explores current developments in genetic profiling, molecular diagnostics, and targeted therapies that have revolutionized breast cancer treatment. Key innovations, such as cyclin-dependent kinases 4/6 (CDK4/6) inhibitors, antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs), have improved outcomes for hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes remarkably. Additionally, emerging treatments, such as PI3K inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and mRNA-based therapies, offer new avenues for targeting specific genetic mutations and improving treatment response, particularly in difficult-to-treat breast cancer subtypes. The integration of liquid biopsy technologies provides a non-invasive approach for real-time monitoring of tumor evolution and treatment response, thus enabling dynamic adjustments to therapy. Molecular imaging and artificial intelligence (AI) are increasingly crucial in enhancing diagnostic precision, personalizing treatment plans, and predicting therapeutic outcomes. As precision medicine continues to evolve, it has the potential to significantly improve survival rates, decrease recurrence, and enhance quality of life for patients with breast cancer. By combining cutting-edge diagnostics, personalized therapies, and emerging treatments, precision medicine can transform breast cancer care by offering more effective, individualized, and less invasive treatment options.https://www.cancerbiomed.org/content/22/4/322breast cancerprecision medicinediagnostic precisionpersonalized therapy |
| spellingShingle | Jingwen Bai Yiyang Gao Guojun Zhang The treatment of breast cancer in the era of precision medicine Cancer Biology & Medicine breast cancer precision medicine diagnostic precision personalized therapy |
| title | The treatment of breast cancer in the era of precision medicine |
| title_full | The treatment of breast cancer in the era of precision medicine |
| title_fullStr | The treatment of breast cancer in the era of precision medicine |
| title_full_unstemmed | The treatment of breast cancer in the era of precision medicine |
| title_short | The treatment of breast cancer in the era of precision medicine |
| title_sort | treatment of breast cancer in the era of precision medicine |
| topic | breast cancer precision medicine diagnostic precision personalized therapy |
| url | https://www.cancerbiomed.org/content/22/4/322 |
| work_keys_str_mv | AT jingwenbai thetreatmentofbreastcancerintheeraofprecisionmedicine AT yiyanggao thetreatmentofbreastcancerintheeraofprecisionmedicine AT guojunzhang thetreatmentofbreastcancerintheeraofprecisionmedicine AT jingwenbai treatmentofbreastcancerintheeraofprecisionmedicine AT yiyanggao treatmentofbreastcancerintheeraofprecisionmedicine AT guojunzhang treatmentofbreastcancerintheeraofprecisionmedicine |